VSPharmtech announced on the 2nd that it signed a memorandum of understanding (MOU) with Micromediome, a company specializing in intestinal bacteria-based biopharmaceuticals, for joint research on new anticancer drugs.
The purpose of this agreement is to conduct joint research to verify the synergy effect of co-administering Micromediome's candidate substance for enhancing the effect of radiotherapy and VS Pharmtech's radiosensitizer 'VS-101' and to derive new usage and dosage.
The two companies have officially named the study 'Comparative Study on the Efficacy of Combination of Intestinal Bacteria for Anticancer Treatment and VS-101' and plan to expand technological exchanges and build a continuous cooperative relationship through this study.
Micromediome is a bio venture founded by Professor Won-Seok Yoon of the Department of Microbiology at Korea University College of Medicine, and focuses on developing immune and anticancer treatments based on various intestinal bacteria, including lactic acid bacteria. In particular, it possesses the highest level of technological prowess in Korea in the field of innovative new drug development using the intestinal microbiome.
“This joint research is a strategic collaboration that combines the core technologies of both companies, and will present new possibilities in the field of radiation-based cancer treatment,” said Park Shin-young, CEO of VSPharmtech. “We expect that it will allow us to develop new drugs and provide patients with more effective treatment options.”
- See more related articles
You must be logged in to post a comment.